MARKET

OKYO

OKYO

OKYO PHARMA LTD
NASDAQ
1.520
+0.010
+0.66%
After Hours: 1.550 +0.03 +1.97% 16:37 08/14 EDT
OPEN
1.520
PREV CLOSE
1.510
HIGH
1.585
LOW
1.490
VOLUME
65.02K
TURNOVER
--
52 WEEK HIGH
3.330
52 WEEK LOW
1.340
MARKET CAP
79.77M
P/E (TTM)
-4.7950
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OKYO last week (0803-0807)?
Weekly Report · 4d ago
Weekly Report: what happened at OKYO last week (0727-0731)?
Weekly Report · 08/03 09:16
OKYO Pharma CSO Increases Stake Ahead of Planned Phase 3 Trial
TipRanks · 07/28 11:28
Okyo Pharma CSO Raj Patil purchases 3,363 shares at $1.49
TipRanks · 07/28 11:25
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share
Benzinga · 07/28 11:08
OKYO Pharma to Present Late-Stage Ophthalmic Pipeline at BTIG Biotechnology Conference 2026
TipRanks · 07/27 11:27
Weekly Report: what happened at OKYO last week (0720-0724)?
Weekly Report · 07/27 09:17
OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial
TipRanks · 07/23 16:27
More
About OKYO
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Webull offers OKYO Pharma Ltd stock information, including NASDAQ: OKYO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OKYO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OKYO stock methods without spending real money on the virtual paper trading platform.